牛牛AI助理已提取核心訊息
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, filed an amendment with the Securities and Exchange Commission on March 6, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 3,404,256 shares of common stock by certain institutional investors. These shares are issuable upon the exercise of warrants that were part of a private placement and registered direct offering that occurred on January 30, 2024. The warrants have an exercise price of $1.05 per share, are currently exercisable, and will expire five and a half years from the date of issuance. Seelos Therapeutics will not receive any proceeds from the sale of shares by the institutional investors but may receive proceeds from any cash exercise of the warrants. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'SEEL'.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, filed an amendment with the Securities and Exchange Commission on March 6, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 3,404,256 shares of common stock by certain institutional investors. These shares are issuable upon the exercise of warrants that were part of a private placement and registered direct offering that occurred on January 30, 2024. The warrants have an exercise price of $1.05 per share, are currently exercisable, and will expire five and a half years from the date of issuance. Seelos Therapeutics will not receive any proceeds from the sale of shares by the institutional investors but may receive proceeds from any cash exercise of the warrants. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'SEEL'.
臨床階段的生物製藥公司Seelos Therapeutics, Inc. 於2024年3月6日向美國證券交易委員會提交了1933年《證券法》規定的註冊聲明修正案。該文件涉及某些機構投資者轉售多達3,404,256股普通股。這些股票可在行使認股權證後發行，認股權證是2024年1月30日私募和註冊直接發行的一部分。認股權證的行使價爲每股1.05美元，目前可行使，自發行之日起五年半到期。Seelos Therapeutics不會從機構投資者出售股票中獲得任何收益，但可能會從認股權證的任何現金行使中獲得收益。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “SEEL”。
臨床階段的生物製藥公司Seelos Therapeutics, Inc. 於2024年3月6日向美國證券交易委員會提交了1933年《證券法》規定的註冊聲明修正案。該文件涉及某些機構投資者轉售多達3,404,256股普通股。這些股票可在行使認股權證後發行，認股權證是2024年1月30日私募和註冊直接發行的一部分。認股權證的行使價爲每股1.05美元，目前可行使，自發行之日起五年半到期。Seelos Therapeutics不會從機構投資者出售股票中獲得任何收益，但可能會從認股權證的任何現金行使中獲得收益。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “SEEL”。
有用
沒用